Since its FDA approval in 2016, Venetoclax, which targets the anti-apoptotic protein BCL2, has been administered to patients with chronic lymphocytic leukemia (CLL), small lymphocytic lymphoma (SLL), or acute myeloid leukemia (AML)39. The gene discussed is BCL2; the disease is acute myeloid leukemia.